John Dee, MS, MBA
John Dee is the founding president and chief executive officer of Novion Pharmaceuticals, a leading neuroscience company focused on sleep apnea. Prior to Novion, he was the president and chief executive officer of Link Medicine Corporation, which was developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, until its acquisition by AstraZeneca in 2012. Dee was also the president and chief executive officer of Hypnion, a pioneering neuroscience company that was focused on sleep disorders, from its founding until its sale to Eli Lilly in 2007. Earlier in his career, Dee spent several years with the management consulting firm, McKinsey & Co., where he led large client service teams of international corporations on major change programs and strategic growth initiatives. Dee holds a Bachelor of Arts in Applied Mathematics and a Master of Science in Engineering from Stanford University, and a Master of Business Administration from Harvard University.
In addition to previously serving as Proclara’s chairman of the board of directors, Dee has been a board director for Verenium, an industrial enzymes company focused on innovative clean technology, as well as a chairman of Bioprocessors, a leading innovator focused on transforming bioprocessing methods for the life sciences industry. He has also engaged in nonprofit work and several community projects, leading a group of San Francisco economists and business leaders in an extensive public policy review of the Bay Area’s economic performance. He additionally has advised the Pacific Presidio Center on the redesign of the Presidio army base into a potential world-class environmental center.